医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PARIS

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today announced the installation of the EOS® imaging system in Japan’s leading spine medical center at Meijo Hospital in Nagoya. The installation is one of the four installations of EOS in Japan since the equipment has received market clearance.

Japanese adoption of the EOS system began in December 2013 with the first installation at Niigata Spine Surgery Center (NSSC) following regulatory approval by Japanese authorities. The current installation at the Meijo Hospital, affiliated with the Nagoya University Hospital, underscores the adoption of EOS by the best Japanese institutions for spine surgery. Meijo Hospital has the highest volume of deformative spine surgeries in Japan.

Professor Noriaki Kawakami, Director of Orthopedic Surgery at Meijo Hospital, said, “Our hospital performs a vital role providing community health services throughout Japan. The installation of EOS in our facilities and throughout Japan is an important step in ensuring that our patients have access to the most beneficial imaging technology available.”

Marie Meynadier, CEO of EOS imaging, said, “We are happy to report rapid adoption of the EOS system in Japan. The Meijo Hospital, one among our four recent installations, demonstrates the positive results from our ongoing market development strategy in the Asia-Pacific region. We are confident that EOS adoption will continue in Japan and throughout the region as other physicians see the value of our technology demonstrated at these hospitals.”

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit www.eos-imaging.com.

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 32 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of 75 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 101 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and Frankfurt (Germany), and offices in Singapore. For further information, please visit www.eos-imaging.com.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 1^st half of 2014, on July 22, 2014 (after market).